In a report released today, Robert Marcus from J.P. Morgan maintained a Buy rating on Insulet (PODD), with a price target of $235.00. The company’s shares closed last Friday at $217.63, close to its 52-week high of $219.86.
According to TipRanks.com, Marcus is a 4-star analyst with an average return of 21.6% and a 90.0% success rate. Marcus covers the Healthcare sector, focusing on stocks such as Nevro Crop, Penumbra, and Glaukos.
Currently, the analyst consensus on Insulet is a Moderate Buy with an average price target of $211.58, which is a 4.2% upside from current levels. In a report issued on April 27, Raymond James also maintained a Buy rating on the stock with a $220.00 price target.
See today’s analyst top recommended stocks >>
Insulet’s market cap is currently $13.57B and has a P/E ratio of 1147.60. The company has a Price to Book ratio of 568.79.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Insulet Corp. is a medical device company. The firm engages in the development, manufacture and marketing of an insulin infusion system for people with insulin-dependent diabetes. It specializes in diabetes supplies, including the OmniPod System as well as other diabetes related products and supplies such as blood glucose testing supplies, traditional insulin pumps, pump supplies, and pharmaceuticals. The company was founded by John L. Brooks III and John T. Garibotto in July 2000 and is headquartered in Acton, MA.
